InsiderTrades.com logo
This Crisis Could Be Worse Than 2008
From Behind the Markets   |   Ad
Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.
In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street.
Benny Sorensen net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Benny Sorensen Biography and Net Worth

Insider of Codiak BioSciences
Dr. Sorensen is CEO of Hemab Therapeutics, a privately held biotech company focused on rare bleeding and thrombosis disorders. Previously, Dr. Sorensen held several positions at Codiak, most recently as Senior Vice President, Strategic Projects and before that, SVP, Head of Clinical Development. Dr. Sorensen joined Codiak from Alnylam Pharmaceuticals, where he was Senior Director of Clinical Research since 2013 leading preclinical as well as clinical, regulatory, medical affairs and commercial development strategies for hematology products. He has more than 15 years of experience in clinical and translational research and management. Before joining Alnylam, Dr. Sorensen was a Global Medical Director at Baxter Healthcare Corporation advancing phase three pivotal development of Adynovate® and Vonvendi®. Prior to Baxter he was the Director of the Haemostasis Research Unit and Honorary Lecturer at Guy’s and St. Thomas’ Hospital & King’s College London School of Medicine, where he led basic translational research and advancement of several clinical trials across Phases I, II, and III. Dr. Sorensen has published extensively in hematology translational and clinical research.

How old is Benny Sorensen?

Dr. Sorensen is currently 48 years old. There are 6 older executives and no younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences is Dr. Douglas Edward Williams Ph.D., Pres, CEO & Director, who is 64 years old. Learn More on Benny Sorensen's age.

How do I contact Benny Sorensen?

The corporate mailing address for Dr. Sorensen and other Codiak BioSciences executives is , , . Codiak BioSciences can also be reached via phone at 617-949-4100 and via email at [email protected]. Learn More on Benny Sorensen's contact information.

Has Benny Sorensen been buying or selling shares of Codiak BioSciences?

Benny Sorensen has not been actively trading shares of Codiak BioSciences during the last ninety days. Most recently, Benny Sorensen sold 8,533 shares of the business's stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $25.67, for a transaction totalling $219,042.11. Learn More on Benny Sorensen's trading history.

Who are Codiak BioSciences' active insiders?

Codiak BioSciences' insider roster includes Nicole Barna (Insider), Konstantin Konstantinov (CTO), Sriram Sathyanarayanan (Insider), and Benny Sorensen (Insider). Learn More on Codiak BioSciences' active insiders.

Benny Sorensen Insider Trading History at Codiak BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2021Sell8,533$25.67$219,042.11View SEC Filing Icon  
6/8/2021Sell8,533$25.67$219,042.11View SEC Filing Icon  
See Full Table

Benny Sorensen Buying and Selling Activity at Codiak BioSciences

This chart shows Benny Sorensen's buying and selling at Codiak BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codiak BioSciences Company Overview

Codiak BioSciences logo
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00
Low: $0.05
High: $6.98

Volume

N/A

Average Volume

1,366,845 shs

Market Capitalization

$58,928.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.71
This Crisis Could Be Worse Than 2008
From Behind the Markets   |   Ad
Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.
In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street.